Paclitaxel plus high-dose cyclosphosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma

British Journal of Haematology

Volumn 103, Issue 3, 1998, Pages 678-683

  Younes, Anas ^a,b   Romaguera, Jorge ^a   Mesina, Ofelia ^a   Hagemeister, Frederick ^a   Sarris, Andreas H ^a   Rodriguez, Maria A ^a   Mclaughlin, Peter ^a   Preti, Hector A ^a   Bachier, Carlos ^a   Cabanillas, Fernando ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cyclophosphamide; Lymphoma; Paclitaxel

Indexed keywords

CIMETIDINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; MESNA; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHRONIC DISEASE; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRADERMAL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PACLITAXEL; RECURRENCE; TREATMENT OUTCOME;

EID: 7844246544     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.01048.x     Document Type: Article

References (17)

1. Armitage, J.O. (1992) Chemotherapy for non-Hodgkin's lymphoma. Current Opinion in Oncology, 4, 840-846.
2. Armitage, J.O. (1993) Treatment of non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 1023-1030.
3. Demirer, T., Rowley, S., Buckner, C.D., Appelbaum, F.R., Lilleby, K., Storb, R., Schiffman, K. & Bensinger, W.I. (1995) Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer, Journal of Clinical Oncology, 13, 1714-1719.
4. Fennelly, D., Schneider, H., Spriggs, D., Bengala, C., Hakes, T., Reich, L., Barakat, R., Curtin, J., Moore, M.A., Hoskins, W., Norton, L. & Crown, J. (1995) Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. Journal of Clinical Oncology, 13, 1160-1166.
5. Fisher, R.I., Gaynor, E.R., Dahlberg, S., Oken, M.M., Grogan, T.M., Mize, E.M., Glick, J.H., Coltman, C.A., Jr & Miller, T.P. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine, 328, 1002-1006.
6. Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chan, J.K., Cleary, M.L., Delsol, G., De Wolf-Peeters, C., Falini, B., Catter, K.C., Grogan, T.M., Isaacson, P.G., Knowles, D.M., Mason, D.Y., Muller-Hermelink, H.-K., Pileri, S.A., Piris, M.A., Ralfkiaer, E. & Warnke, R.A. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84, 1361-1392.
7. Hryniuk, W. (1993) CHOP versus m-BACOD in non-Hodgkin's lymphoma. (Letter). New England Journal of Medicine, 328, 581.
8. Press, O., Leblanc, M., O'Rourke, T., Gagnet, S., Chapman, R., Blacerzak, S. & Fisher, R. (1998) Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphoma: Southwest Oncology Group Trial 9246. Journal of Clinical Oncology, 16, 574-578.
9. Rodriguez, M.A., Cabanillas, F.C., Velasquez, W., Hagemeister, F.B., McLaughlin, P., Swan, F. & Romaguera, J.E. (1995) Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. Journal of Clinical Oncology, 13, 1734-1741.
10. Shipp, M.A., Harrington, D.P., Anderson, J.R., Armitage, J.O., Bonadonna, G., Brittinger, G., Cabanillas, F., Canellos, G.P., Coiffier, B., Connors, J.M., Cowan, R.A., Crowther, D., Dahlberg, S., Engelhard, M., Fisher, R.I., Gisselbrecht, C., Horning, S.J., Lepage, E., Lister, T.A., Meerwaldt, J.H., Montserrat, E., Nissen, N.I., Oken, M.M., Peterson, B.A., Tondini, C., Velasquez., W.A. & Yeap, B.Y. (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. New England Journal of Medicine, 329, 987-994.
11. Tolcher, A.W., Cowan, K.H.., Noone, M.H., Denicoff, A.M., Kohler, D.R., Goldspiel, B.R., Barnes, C.S., McCabe, M., Gossard, M.R., Zujewski, J. & O'Shaughnessy, J.A. (1996) Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating actor in metastatic breast cancer patients. Journal of Clinical Oncology, 14, 95-102.
12. Velasquez, W.S., Cabanillas, F. Salvador, P., McLaughlin, P., Fridrik, M. Tucker, S., Jagannath, S., Hagemeister, F.B., Redman, J.R., Swan, F. & Barlogie, B. (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood, 71, 117-122.
13. Velasquez, W.S., McLaughlin, P., Tucker, S., Hagemeister, F.B., Swan, F., Rodriguenz, M.A., Romaguera, J., Rubenstein, E. & Cabanillas, F. (1994) ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. Journal of Clinical Oncology, 12, 1169-1176.
14. Wilson, W.H., Bryant, G., Bates, S., Fojo, A., Wittes, R.E. Steinberg, S.M., Kohler, D.R., Jaffe, E.S. Herdt, J., Cheson, B.D. & Chabner, B.A. (1993) EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. Journal of Clinical Oncology, 11, 1573-1582.
15. Wilson, W.H., Chabner, H.A., Bryant, G., Bates, S., Fojo, A., Regis, J., Jaffe, E., Steinberg, S.M., Goldspiel, B.R., Cheson, B. & Wittes, R.E. (1995) Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. Journal of Clinical Oncology, 13, 381-386.
16. Younes, A., Ayoub, J.P., Sarris, A., Hagemeister, F., North, L., Pate, O., McLaughlin, P., Rodriguez, M.A., Romaguera, J., Kurzrock, R., Preti, A., Bachier, C., Smith, T. & Cabanillas, F. (1997a) Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. British Journal of Haematology, 96, 328-332.
17. Younes, A., Ayoub, J.P., Sarris, A., North, L., Pate, O., McLaughlin, P., Rodriguez, A., Romaguera, J., Hagemeister, F., Bachier, C., Preti, A. & Cabanillas, F. (1997b) Paclitaxel (Taxol(R)) for the treatment of lymphoma. Annals of Oncology, 8, 129-131.